<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03744585</url>
  </required_header>
  <id_info>
    <org_study_id>A-FR-60000-006</org_study_id>
    <nct_id>NCT03744585</nct_id>
  </id_info>
  <brief_title>Cabozantinib Real-life Use for Advanced Renal Cell Carcinoma in France: a Retrospective Descriptive Non-interventional Study of 2 Cohorts.</brief_title>
  <acronym>CABOREAL</acronym>
  <official_title>Cabozantinib Real-life Use for Advanced Renal Cell Carcinoma in France: a Retrospective Descriptive Non-interventional Study of 2 Cohorts.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to describe the real-life conditions of use and
      exposure of cabozantinib in France in two cohorts defined by their treatment initiation
      period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 6, 2018</start_date>
  <completion_date type="Actual">July 7, 2019</completion_date>
  <primary_completion_date type="Actual">June 7, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of treatment exposure</measure>
    <time_frame>during the whole study period for a maximum of 28 to 31 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose prescribed at initiation</measure>
    <time_frame>during the whole study period for a maximum of 28 to 31 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Daily Dose</measure>
    <time_frame>during the whole study period for a maximum of 28 to 31 months</time_frame>
    <description>average daily dose received by subject during the treatment exposure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with ≥1 temporary interruptions</measure>
    <time_frame>during the whole study period for a maximum of 28 to 31 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of interruptions per subject</measure>
    <time_frame>during the whole study period for a maximum of 28 to 31 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with ≥1 dose modification(s)</measure>
    <time_frame>during the whole study period for a maximum of 28 to 31 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with permanent discontinuations</measure>
    <time_frame>during the whole study period for a maximum of 28 to 31 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival of subjects since cabozantinib initiation</measure>
    <time_frame>during the whole study period for a maximum of 28 to 31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival of subjects since RCC diagnosis.</measure>
    <time_frame>during the whole study period for a maximum of 28 to 31 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival of subjects since metastatic diagnosis</measure>
    <time_frame>during the whole study period for a maximum of 28 to 31 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">450</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>Subjects who received at least one dose of cabozantinib during the Authorization for Use (ATU) period (12/09/2016 to 09/12/2016) for the treatment of advanced Renal Cell Carcinoma (RCC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <description>Subjects who received at least one dose of cabozantinib during the first six months after the ATU period (10/12/2016 to 16/02/2018).</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Cohort 1: subjects who received at least one dose of cabozantinib during the ATU period
        (12/09/2016 to 09/12/2016) for the treatment of advanced RCC. Cohort 2: subjects who
        received at least one dose of cabozantinib during the first six months after the ATU period
        (10/12/2016 to 16/02/2018).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any subjects from the participating sites (dead or alive) who have received at least
             one dose of cabozantinib within the ATU program or between 10/12/2016 and 16/02/2018
             and for whom the medical file is available

        Exclusion Criteria:

          -  Patients alive at study initiation who have not received information notice

          -  who have opposed to data collection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ipsen Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ipsen Central Contact</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>November 14, 2018</study_first_submitted>
  <study_first_submitted_qc>November 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2018</study_first_posted>
  <last_update_submitted>July 24, 2019</last_update_submitted>
  <last_update_submitted_qc>July 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

